|
Session 148
Poster Abstracts
Tenofovir-Associated Renal Dysfunction
Monday, 1 - 4 pm
Poster Hall |
832
 |
Tenofovir and Renal Dysfunction in Clinical Practice
Richard Moore*, J Keruly, and J Gallant
Johns Hopkins Univ, Baltimore, MD, US |
| 833 |
Risk Factors for Tenofovir-associated Nephrotoxicity Identified in an HIV Clinic Cohort
Homan Wai*, T Katsivas, C Ballard, E Barber, and C Mathews
Univ of California, San Diego, US |
834
|
Tenofovir Treatment Is Associated with a Decrease in Calculated Glomerular Filtration Rates in a Large Observational Cohort
C Fux1, M Simcock2, M Wolbers2, H Bucher2, M Cavassini3, M Opravil4, P Vernazza5, B Hirschel6, E Bernasconi7, Hansjakob Furrer*1, and Swiss HIV Cohort Study (SHCS)
1Univ Hosp Berne, Switzerland; 2Basel Inst for Clin Epidemiology, Switzerland; 3Ctr Hosp Univ Vaudois Lausanne, Switzerland; 4Univ Hosp, Zurich, Switzerland; 5Kantonsspital St Gallen, Switzerland; 6Geneva Univ Hosp, Switzerland; and 7Hosp Civico Lugano, Switzerland |
| 835 |
Increased Renal Impairment in Patients Receiving TDF+PI vs TDF+NNRTI
Miguel Goicoechea*1, S Liu2, B Best1, S Sun1, S Jain1, C Kemper3, M Witt4, C Diamond5, R Haubrich1, S Louie2, and California Collaborative Treatment Group (CCTG) 578 Team
1Univ of California, San Diego, US; 2Univ of Southern California, Los Angeles, US; 3Santa Clara Valley Med Ctr, San Jose, CA, US; 4LA Biomed Res Inst at Harbor-Univ of California, Los Angeles Med Ctr, Torrance, US; and 5Univ of California, Irvine, US |
|
